CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF
Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.
Saved in:
| Main Author | |
|---|---|
| Format | Patent |
| Language | English |
| Published |
19.03.2020
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention. |
|---|---|
| AbstractList | Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention. |
| Author | BURNIER, John |
| Author_xml | – fullname: BURNIER, John |
| BookMark | eNrjYmDJy89L5WRwdQ6KDA5x9PHx9HNVCPBwDPJ1dHYNDfF0dvRRcPRzUfB1DfHwdwlW8HdTCAhyDXAMcgzx9PcDS4UGuyqEeLgGufq78TCwpiXmFKfyQmluBmU31xBnD93Ugvz41OKCxOTUvNSS-NBgIwMjAwMLcyMLc0dDY-JUAQBf_C7B |
| ContentType | Patent |
| DBID | EVB |
| DatabaseName | esp@cenet |
| DatabaseTitleList | |
| Database_xml | – sequence: 1 dbid: EVB name: esp@cenet url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP sourceTypes: Open Access Repository |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Chemistry Sciences |
| ExternalDocumentID | US2020087287A1 |
| GroupedDBID | EVB |
| ID | FETCH-epo_espacenet_US2020087287A13 |
| IEDL.DBID | EVB |
| IngestDate | Fri Jul 19 15:56:52 EDT 2024 |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | false |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-epo_espacenet_US2020087287A13 |
| Notes | Application Number: US201916411598 |
| OpenAccessLink | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20200319&DB=EPODOC&CC=US&NR=2020087287A1 |
| ParticipantIDs | epo_espacenet_US2020087287A1 |
| PublicationCentury | 2000 |
| PublicationDate | 20200319 |
| PublicationDateYYYYMMDD | 2020-03-19 |
| PublicationDate_xml | – month: 03 year: 2020 text: 20200319 day: 19 |
| PublicationDecade | 2020 |
| PublicationYear | 2020 |
| RelatedCompanies | SARcode Bioscience Inc |
| RelatedCompanies_xml | – name: SARcode Bioscience Inc |
| Score | 3.2516181 |
| Snippet | Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed.... |
| SourceID | epo |
| SourceType | Open Access Repository |
| SubjectTerms | CHEMISTRY HETEROCYCLIC COMPOUNDS METALLURGY ORGANIC CHEMISTRY |
| Title | CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF |
| URI | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20200319&DB=EPODOC&locale=&CC=US&NR=2020087287A1 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8MwED_GFPVNp-LHlICyt6Jb23V5GNKlKUXoB_2Q-TSWLANBuuEq_vteuk33tLckB0dy8Mvll9xdAB4pVYOpolPjeYZws5ScGchDBoathKSyJ-lc6eTkMOoHhfU6tscN-NzmwtR1Qn_q4oiIKIl4r-r9evl_ieXVsZWrJ_GBQ4sXPx96nQ071pFWiEBvNORJ7MWsw9iwyDpRupYNHOQHLnKlAzxIOzoAjL-NdF7Kctep-KdwmKC-sjqDhipbcMy2f6-14CjcPHljc4O-1Tlwlr5nuYv0O-IkCdw0dBkvcl3RgLiRR0KeB7GXkdgnaNjEXd8_1aIi4yQPeMpj_wIefJ6zwMD5TP6WPymy3cmbl9AsF6W6AtIXtmk73anlSOQ5va6wlGnPTUGlI5yZ1buG9j5NN_vFt3Ciuzreqkvb0Ky-vtUdOuBK3Nd2-wWGP4Mt |
| link.rule.ids | 230,309,783,888,25578,76884 |
| linkProvider | European Patent Office |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8MwED_GFOebTsWPqQFlb0W3tmvzMKRLU4raD_oh82ksbQaCdMNV_Pe9dpvuaW8hB8fl4JfLL7m7ANxTKs2ppFPlMUe4aTLLFeQhpqJLkdGsn9GZrIqTPX_gptrzWB834HNTC1P3Cf2pmyMiojLEe1nv14v_Syy7zq1cPogPnJo_OcnQ7q7ZcZVphQi0R0MeBnbAuowN07jrRyuZaSA_sJAr7eEh26w67fO3UVWXstgOKs4R7IeoryiPoSGLNrTY5u-1Nhx46ydvHK7RtzwBzqL3OLGQfvuchK4VeRbjaVJ1NCCWbxOPJ25gxyRwCDo2tFb3T7UojTlJXB7xwDmFO4cnzFXQnsnf8idpvG28egbNYl7IcyADoau60ZtqRoY8p98TmlT1mSpoZggj1_oX0Nml6XK3-BZabuK9TnBNL1dwWImq3Kse7UCz_PqW1xiMS3FT-_AX1U-GHQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=CRYSTALLINE+PHARMACEUTICAL+AND+METHODS+OF+PREPARATION+AND+USE+THEREOF&rft.inventor=BURNIER%2C+John&rft.date=2020-03-19&rft.externalDBID=A1&rft.externalDocID=US2020087287A1 |